Therapy News and Research

RSS

$FDA approves Medtronic software update that will help detect fractures in cardiac defibrillator leads$

FDA approves Medtronic software update that will help detect fractures in cardiac defibrillator leads

The U.S. Food and Drug Administration today announced approval of a software update from Medtronic that will help detect fractures of the company's Sprint Fidelis cardiac defibrillator lead.

4 Sep 2008

FDA 'fast track' granted to BioMS Medical for lead drug, dirucotide for the treatment of multiple sclerosis

BioMS Medical Corp has announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients.

4 Sep 2008

Celgene receives FDA 'fast track' for Amrubicin in small cell lung cancer after first-line chemotherapy

Celgene Corporation today announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.

4 Sep 2008

Anadis to commercialise "BioGard" adjunctive therapy for HIV/AIDS

Anadis announced today its commercialization of a new product, BioGard, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS.

4 Sep 2008

Clinical trial advances cystic fibrosis therapy

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.

4 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Vimpat (lacosamide) approved in Europe

UCB announced today that the European Commission (EC) has approved Vimpat (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.

3 Sep 2008

MRSA breast infections controllable in nursing mothers, researchers find

Many nursing mothers who have been hospitalized for breast abscesses are afflicted with the "superbug" methicillin-resistant Staphylococcus aureus, or MRSA, but according to new research by UT Southwestern Medical Center physicians, conservative treatment can deal with the problem.

3 Sep 2008

Monitoring immune responses in disease

A recent study published in Clinical Immunology, the official journal of the Clinical Immunology Society (CIS), describes a new method enabling the detection of multiple parameters of single human cells.

3 Sep 2008

Further analysis from ATHENA study showed Multaq (Dronedarone) reduced risk of stroke in patients with atrial fibrillation

The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.

3 Sep 2008

FDA authorizes INDA for recombinant human C1 inhibitor in kidney transplantation

Biotech company Pharming Group NV has announced that the US Food and Drug Administration (FDA) has authorized a clinical study with recombinant human C1 inhibitor (rhC1INH) for the treatment of antibody-mediated rejection (AMR) in kidney transplantation. Dr. Hans Sollinger of the University of Wisconsin, Madison will conduct the clinical trial with rhC1INH under an Investigator IND from the FDA.

3 Sep 2008

New hope for treating common form of inherited neuromuscular disease

Treatments that ramp up production of the tiny "motors" that power cells may have promise for treating one of the most common forms of inherited neuromuscular disease, according to a report in the September Cell Metabolism, a Cell Press publication. Neuromuscular disorders caused by defects in those mitochondrial motors affect a large number of children and adults worldwide, but today remain without treatment, the researchers said.

3 Sep 2008

Anadis Ltd's clinical trial against mucositis approved in Israel

Anadis Ltd., an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH).

3 Sep 2008

Artists should become involved with fight against HIV/AIDS in Southern Africa, official says

Local and regional artists and celebrities should become increasingly involved in the fight against HIV/AIDS in Southern Africa because they understand the cultures affected by the disease, Eugene Marillier-Malotana, founder and director of the Southern African Development Community Artists AIDS Festival and the SADC Artists AIDS Support Network, said recently, the Financial Gazette/AllAfrica.com reports.

2 Sep 2008

Advances in cell therapy bring cure for diabetes step closer

Affecting eight percent of America's population, diabetes can lead to blindness, kidney failure, strokes and heart disease. Thanks to Tel Aviv University researchers, a new cure -- based on advances in cell therapy -- may be within reach.

2 Sep 2008

Hopkins researchers piece together gene "network" linked to schizophrenia

Reporting this week in the Archives of General Psychiatry, researchers at the Johns Hopkins University School of Medicine have uncovered for the first time molecular circuitry associated with schizophrenia that links three previously known, yet unrelated proteins.

2 Sep 2008

Pre-hospital treatment on the way to percutaneous coronary intervention

For patients with acute ST-segment-elevation AMI (STEMI) within 12 hours after symptom onset and with persistent ST-segment elevation, or new or presumednew left bundle-branch block with concomitant ST-segment elevation, restoring coronary blood flow as early as possible is the main goal of reperfusion strategies.

2 Sep 2008

Safety of antithrombotic treatment in acute coronary syndromes

The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion.

2 Sep 2008

The effects of A2 inhibitor Darapladib on human coronary athlerosclerotic plaque

A twelve month study of treatment with darapladib concluded that,Lp-PLA2 inhibition with darapladib prevented necrotic core expansion, a key determinant of plaque vulnerability.

2 Sep 2008

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome

Data from a phase II study of an investigational drug designed to block formation of blood clots show potential for added protection against a second heart attack or stroke among patients who are already taking state-of-the-art prevention therapy.

2 Sep 2008

Therapy News and Research

FDA approves Medtronic software update that will help detect fractures in cardiac defibrillator leads

FDA 'fast track' granted to BioMS Medical for lead drug, dirucotide for the treatment of multiple sclerosis

Celgene receives FDA 'fast track' for Amrubicin in small cell lung cancer after first-line chemotherapy

Anadis to commercialise "BioGard" adjunctive therapy for HIV/AIDS

Clinical trial advances cystic fibrosis therapy

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Vimpat (lacosamide) approved in Europe

MRSA breast infections controllable in nursing mothers, researchers find

Monitoring immune responses in disease

Further analysis from ATHENA study showed Multaq (Dronedarone) reduced risk of stroke in patients with atrial fibrillation

FDA authorizes INDA for recombinant human C1 inhibitor in kidney transplantation

New hope for treating common form of inherited neuromuscular disease

Anadis Ltd's clinical trial against mucositis approved in Israel

Artists should become involved with fight against HIV/AIDS in Southern Africa, official says

Advances in cell therapy bring cure for diabetes step closer

Hopkins researchers piece together gene "network" linked to schizophrenia

Pre-hospital treatment on the way to percutaneous coronary intervention

Safety of antithrombotic treatment in acute coronary syndromes

The effects of A2 inhibitor Darapladib on human coronary athlerosclerotic plaque

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News